General
Preferred name
NAPHAZOLINE
Synonyms
NAPHAZOLINE HYDROCHLORIDE ()
Albalon ()
Rhinantin ()
NAPHAZOLINE HCL ()
AK-Con ()
Naphcon-a ()
Clear Eyes ()
All Clear ()
Naphazoline (nitrate) ()
Naphazoline (hydrochloride) ()
Naphthazoline ()
Naphthazoline (nitrate) ()
Naphthazoline (hydrochloride) ()
Vasocon ()
Antistin-Privine ()
Naphazoline hydrochloride component of naphcon-a ()
Nafazair ()
Naphcon Forte ()
Naphazoline hydrochloride component of visine ()
NSC-35711 ()
Naphazoline hydrochloride component of opcon-a ()
Naphaz HCl ()
Gppe Nsl Soln ()
Naphazoline hydrochloride component of visine-a ()
Opcon ()
Naphazoline hydrochloride component of vasocon-a ()
Naphazoline Nitrate ()
Nafazolina ()
Nafazolin ()
Naphazoline dihydrochloride ()
Naphazoline-d4 (hydrochloride) ()
P&D ID
PD009276
CAS
550-99-2
35412-62-5
10061-11-7
835-31-4
5144-52-5
Tags
available
drug
Approved by
FDA
First approval
1971
Drug indication
Itching
Hyperaemia
pterygium
Neoplasm
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Naphazoline (Naphthazoline) hydrochloride is a potent ¦Á-adrenergic receptor agonist. Naphazoline hydrochloride reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline hydrochloride reduces the levels of inflammatory factors (TNF-¦Á, IL-1¦Â and IL-6), cytokines (IFN-¦Ã and IL-4), IgE, GMCSF, and NGF. Naphazoline hydrochloride can be used for non-bacterial conjunctivitis research[1][2].
PRICE
29
HALF-LIFE
Half life has not been determined but effects last for 4 to 8 hours[L5807]. Other imidazoline compounds have half lives varying from 2 to 12 hours[T530].
ABSORPTION
Absorption data for naphazoline are scarce but imidazoline compounds in general are weakly basic and lipophilic, with high bioavailability from the gastrointestinal tract[T530].
PHARMACODYNAMICS
Naphazoline is a sympathomimetic alpha adrenergic agonist that acts to vasoconstrict nasal or ocular arterioles, resulting in reduced congestion at the site of administration[L5804,L5807].
INDICATION
Naphazoline is indicated for use as OTC eyedrops for ocular vasoconstriction or as a nasal preparation for nasal congestion[A176558,L5804,L5807].
ROE
Imidazoline compounds undergo some hepatic metabolism but a large fraction of the dose may be excreted unchanged in the urine[T530]. Urinary excretion is higher with more acidic urine[T530].
METABOLISM
Metabolism data for naphazoline are scarce. Imidazoline compounds undergo some hepatic metabolism but a large fraction of the dose may be excreted unchanged in the urine[T530].
DESCRIPTION
Marketed formulations may contain naphazoline hydrochloride (PubChem CID 11079) or naphazoline nitrate (PubChem CID 16218420).
(GtoPdb)
MOA
Naphazoline is a vasoconstrictor that functions by stimulating alpha adrenergic receptors in arterioles leading to decreased congestion at the site of administration[L5804].; ; Naphazoline causes the release of norepinephrine in sympathetic nerves[A176567]. Norepinephrine binds to alpha adrenergic receptors and causes vasoconstriction[A176567]. Naphazoline is also a mild beta adrenergic receptor agonist, which can cause rebound vasodilation after the alpha adrenergic stimulation has ended[A176567]. Naphazoline's release of norepinephrine also triggers a negative feedback loop which decreases production of norepinephrine, which can lead to rhinitis medicamentosa after long term use when naphazoline is stopped[A176567].
TOXICITY
In high doses or when ingested, naphazoline can lead to central nervous system depression (which can progress to coma and death), hypothermia, bradycardia, and death[A176558]. This effect is especially pronounced in children under 6 years[A176558,A176564].; ; Long term use of naphazoline can lead to rhinitis medicamentosa once naphazoline is stopped[A176567]. This condition is a result of norepinephrine release by naphazoline triggering a negative feedback loop[A176567].; ; Safety and effectiveness in children under 12 has not been established[F4214]. Studies in elderly patients have yet to be performed[F4214]. Risk in pregnancy, breast feeding, and on overall fertility have not been established, though pregnant and breast feeding patients should consider the risk and benefit before starting naphazoline treatment[F4214].
DESCRIPTION
Naphazoline (Naphthazoline) is a potent ¦Á-adrenergic receptor agonist. Naphazoline reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline reduces the levels of inflammatory factors (TNF-¦Á, IL-1¦Â and IL-6), cytokines (IFN-¦Ã and IL-4), IgE, GMCSF, and NGF. Naphazoline can be used for non-bacterial conjunctivitis research[1][2].
PRICE
41
DESCRIPTION
Naphazoline (Naphthazoline) nitrate is an ¦Á-adrenergic receptor agonist. Naphazoline nitrate reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline nitrate reduces the levels of inflammatory factors (TNF-¦Á, IL-1¦Â and IL-6), cytokines (IFN-¦Ã and IL-4), IgE, GMCSF, and NGF. Naphazoline nitrate can be used for non-bacterial conjunctivitis research[1][2].
DESCRIPTION
Naphazoline hydrochloride (Naphazoline HCl) is an adrenergic vasoconstrictor agent used as a decongestant.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Naphazoline (Naphcon-a) is a sympathomimetic compound with marked alpha adrenergic activity. Naphazoline can be used as a vasoconstrictor with a rapid action in reducing swelling when applied to mucous membrane.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Naphazoline is a sympathomimetic alpha adrenergic agonist. Naphazoline is a sympathomimetic vasoconstrictor used for the symptomatic relief of redness and itching of the eye, and nasal congestion.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
28
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
84
Molecular Weight
210.12
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
2.38
TPSA
24.39
Fraction CSP3
0.21
Chiral centers
0.0
Largest ring
6.0
QED
0.81
QED
0.81
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Adrenergic Receptor
α-adrenergic receptor
ADRA1A, ADRA2A
Interleukin Related
TNF Receptor
VEGFR
Member status
virtual
MOA
alpha-Adrenoceptor Antagonists
Adrenergic Receptor agonist
Indication
eye irritation
Pathway
GPCR/G protein
Neuroscience
Apoptosis
Immunology/Inflammation
Neuronal Signaling
Protein Tyrosine Kinase/RTK
Therapeutic Class
Anticancer Agents
Source data
